LAVAL, Quebec, May 21, 2013 /CNW/ - Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced the election of ten directors nominated at its 2013 annual meeting of shareholders today.

LAVAL, QC, May 20, 2013 /CNW Telbec/ - J. Michael Pearson, Chairman and CEO of Valeant Pharmaceuticals International and Jacques Dessureault, President and CEO of Valeant Canada, invite the media to the inauguration of the company's international ...

Valeant Pharmaceuticals Intl Inc (NYSE:VRX) was in 37 hedge funds' portfolio at the end of March. VRX shareholders have witnessed an increase in enthusiasm from smart money recently.

Valeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, neurology and ...

LAVAL, Quebec, April 25, 2013 /CNW/ - Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant") today announced the expiration of the tender offer (the "Offer") by a subsidiary of Valeant Pharmaceuticals International ("VPI") to ...

Canada's Valeant Pharmaceuticals International Inc. is nearing a deal to acquire eye care company Bausch & Lomb Inc. from private equity owner Warburg Pincus LLC for about $9-billion (U.

LAVAL, Quebec, May 10, 2013 /CNW/ - Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced today that it has provided additional information related to the proposal to continue Valeant into British Columbia (the "Continuance") ...

LAVAL, Quebec, May 2, 2013 /CNW/ - Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) announced that we agreed this afternoon that the launch of efinaconazole, our topical product candidate for the treatment of onychomycosis, will not ...

Drug maker Valeant Pharmaceuticals International Inc. is in talks to acquire rival Actavis Inc. for more than $13 billion, according to people familiar with the matter, in what would rank as one of the biggest health-care deals this year.

LAVAL, Quebec, April 24, 2013 /CNW/ - Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced that it has received approval by the Antimonopoly Committee of Ukraine (the "AMC") of its proposed acquisition of Obagi Medical ...